Invion Ltd
ASX:IVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Invion Ltd
ASX:IVX
|
AU |
Intrinsic Value
The intrinsic value of Invion Ltd (IVX) under the Base Case is 0.069 AUD per share.
Compared with the current market price of 0.035 AUD, the stock appears
Undervalued by 49% .
The intrinsic value is calculated using the DCF method. The model assumes revenue returns to growth: about 33% a year over the next five years, after falling about 30% a year over the last five years. Net margin recovers from -1464% last year to -100% by 2033. The forecast years subtract value, so the estimate rests entirely on the years after 2033.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Invion Does
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases.
- Headquarters
- Australia AU
- IPO date
- Feb 15, 2010
Earnings Waterfall
Invion Ltd
The intrinsic value for Invion Ltd (IVX) under the Base Case is 0.069 AUD.
Compared with the current market price of 0.035 AUD, the stock appears Undervalued by 49% .